After months of experimentation in partnership with some world-class schools of medicine and top-tier diagnostic providers, the much-anticipated T-Cell Test from Hyris, based on innovative qPCR technology, is finally available for the European market with a CE-IVD mark. The new Test will change the way laboratories and diagnostic providers track and monitor T-cell patients' immunity to SARS-CoV-2, leveraging the unique characteristics of the Hyris System™.

A scientific paper recently published in Nature Biotechnology reveals new research regarding how we track and monitor T-cell patients' immunity to SARS-CoV-2, leveraging the unique characteristics of Hyris System™. The study results from a joint effort of an international research team from the Icahn School of Medicine at Mount Sinai, Singapore Duke-NUS Medical School, laboratory diagnostic service providers Synlab, and Hyris.

National ad campaign will encourage patients to ask doctors about superior NGS diagnostics

Baylor Genetics, a joint venture of H.U. Group Holdings, Inc. and the No. 1 NIH-funded genetics program at Baylor College of Medicine in the U.S., and SRL, Inc., a consolidated subsidiary of H.U. Group Holdings, Inc. located in Tokyo, Japan, establish agreement for exome and genome sequencing services.

Expanding their mission-based diagnostics services

Hyris developed a rapid T-Cell test to track patients' immunity levels to SARS-CoV-2 for global clinical and research use after having inked an exclusive licensing agreement with Duke-NUS Medical School. This new solution leverages the power of the renowned HYRIS bCUBE™ and the whole Hyris SystemTM. This disruptive platform enables genetic testing in any setting, at any time, with results available in real-time through its AI-powered platform.

Hyris developed a rapid T-cell test to track patients' immunity levels to SARS-CoV-2 for global clinical use after having inked an exclusive licensing agreement with Duke-NUS Medical School. This new solution leverages the Hyris SystemTM, a proprietary platform that enables genetic testing in any setting, at any time, with results available in real-time through its AI-powered platform.

As new mutations of SARS-CoV-2 keep spreading worldwide, Hyris keeps monitoring its test kits effectiveness, performing routine analysis of SARS-CoV-2 variants to safeguard public health and the product's quality by assessing the potential impact of new strains on sensitivity and specificity.